Search - tctmd.com

Displaying 201 - 220 of 260

Sort: Relevancy | Date

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

March 11, 2018

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

February 11, 2018

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

News Daily News

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

January 22, 2018

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

January 18, 2018

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Long-Awaited Hypertension Guidelines Released at AHA

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

November 13, 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

October 30, 2017

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

News Daily News

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

October 18, 2017

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

News Daily News

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

October 13, 2017

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

News Daily News

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

October 09, 2017

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

News Daily News

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

October 06, 2017

Generic ARBs Linked to Increased Adverse Events

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

FDA Grants HeartWare LVAD a Destination Therapy Indication

News Daily News

FDA Grants HeartWare LVAD a Destination Therapy Indication

September 28, 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

September 24, 2017

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

News Daily News

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

September 21, 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

September 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.